Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia

Monday, January 9, 2023 1 min read

Key Takeaway: Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia

Full Press Release Details

Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia.